Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 5/20 | 0.54 |
| ▸ | ARF6 | P62330 | 6/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278581 | 0.92 | KCNQ3 (0.52) | PSDARF6KCNQ3KCNQ2ALPL | |
| SCHEMBL19084678 | 0.90 | PSD (0.52) | PSDARF6PLATMEN1NPC1 | |
| SCHEMBL19084688 | 0.85 | PSD (0.51) | PSDARF6PLATKCNQ3KCNQ2 | |
| SCHEMBL1278782 | 0.85 | ARF6 (0.58) | PSDARF6PLATKCNQ3KCNQ2 | |
| SCHEMBL19084538 | 0.85 | ARF6 (0.58) | PSDARF6PLATKCNQ3KCNQ2 | |
| SCHEMBL19084616 | 0.84 | PSD (0.52) | PSDARF6PLATKCNQ3KCNQ2 | |
| SCHEMBL19084679 | 0.84 | PSD (0.52) | PSDARF6PLATKCNQ3KCNQ2 | |
| SCHEMBL1279185 | 0.83 | KCNQ3 (0.54) | PSDKCNQ3KCNQ2ALPLALPI | |
| SCHEMBL1279346 | 0.83 | ALPL (0.44) | PSDKCNQ3KCNQ2ALPLALPI | |
| SCHEMBL19084535 | 0.81 | PSD (0.54) | PSDARF6PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885PLAT 3989/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885PLAT 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.